Clinical Trials
29
Trial Phases
3 Phases
Drug Approvals
8
Drug Approvals
Melphalan Hydrochloride for Injection
- Product Name
- 注射用盐酸美法仑
- Approval Number
- 国药准字HJ20180073
- Approval Date
- Nov 26, 2024
Melphalan Hydrochloride for Injection
- Product Name
- 注射用盐酸美法仑
- Approval Number
- H20180073
- Approval Date
- Mar 16, 2020
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment
- Conditions
- Advanced Solid TumorsHematologic Malignancies
- Interventions
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-06-25
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT07036133
- Locations
- 🇺🇸
TOI Clinical Research, Cerritos, California, United States
🇺🇸Gabrail Cancer Center, Canton, Ohio, United States
To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL
- Conditions
- Peripheral T Cell Lymphoma
- Interventions
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-07-24
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 504
- Registration Number
- NCT06072131
- Locations
- 🇺🇸
University of California, San Francisco Fresno, Clovis, California, United States
🇺🇸University of California, Los Angeles Hem/ Onc Clinical Research Unit, Suite 600, Santa Monica, California, United States
🇺🇸Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System Memorial Cancer Institute, Pembroke Pines, Florida, United States
This Study is to Assess the Efficacy of Difamilast Ointment in Mild to Moderate Atopic Dermatitis(AD)
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 153
- Registration Number
- NCT05608343
- Locations
- 🇺🇸
AllerVie Health, Birmingham, Alabama, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
🇺🇸NEA Baptist Clinic-Dermatology, Jonesboro, Arkansas, United States
A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis
- First Posted Date
- 2022-10-07
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 542
- Registration Number
- NCT05571943
- Locations
- 🇺🇸
Qualmedica Research, LLC, Bowling Green, Kentucky, United States
🇺🇸AllerVie Health, Birmingham, Alabama, United States
🇺🇸Elite Clinical Studies, LLC, Phoenix, Arizona, United States
PK Study on Ready-to-Use Injection (VSLI-RTU) 1 Vial & 3 Vial Formulation Marqibo® in Hematological Malignant Patients
- Conditions
- Hematologic Diseases
- Interventions
- First Posted Date
- 2020-01-28
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Acrotech Biopharma Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT04243434
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next